Absci reports Q4 net loss $29.6M, advances ABS-201 trial, appoints new CMO

Absci Corp

Dosed first three cohorts in SAD portion of Phase 1/2a HEADLINE trial for ABS-201; well-tolerated with favorable emerging safety.
Net loss Q4 2025 $29.6M vs $29.0M prior year; full year net loss $115.2M vs $103.1M.
Cash, equivalents, and marketable securities $144.3M as of Dec 31, 2025; sufficient to fund operations into first half 2028.
Appointed Ransi Somaratne, M.D. (former Vertex SVP) as Chief Medical Officer to lead clinical strategy.
Interim proof-of-concept data for ABS-201 expected H2 2026; Phase 2 endometriosis trial initiation planned Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.